Cardiac hypertrophy: Molecular and cellular events;Hipertrofia cardiaca: Eventos moleculares y celulares

Revista Espanola de Cardiologia

Volumn 59, Issue 5, 2006, Pages 473-486

  Carreño, Juan Eduardo ^a   Apablaza, Felipe ^a   Ocaranza, María Paz ^a   Jalil, Jorge E ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Cardiac hypertrophy; Cell events; Molecular events

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ACTIN; ANGIOTENSIN 1 RECEPTOR; ATRIAL NATRIURETIC FACTOR; ENDOTHELIN RECEPTOR; FIBROBLAST GROWTH FACTOR; GLYCOPROTEIN GP 130; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIM PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; MYOSIN HEAVY CHAIN BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE C; PROTEIN P21; RAF PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SOMATOMEDIN; STRESS ACTIVATED PROTEIN KINASE; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; XANTHINE OXIDASE;

CELL GROWTH; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENETIC MARKER; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PHENOTYPE; PROGNOSIS; PROTEIN SYNTHESIS; REVIEW;

EID: 33745432344     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13087900     Document Type: Review

References (157)

1. Liang F, Gardner DG. Mechanical strain activates BNG gene transcription through a p38/NF-kappaB-dependent mechanism. J Clin Invest 1999;104:1603-12.
2. Frey N, Katas HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580-9.
3. Levy D, Garrison RJ, Savage DD. Prognosis implications of echocardiographically determinad left ventricluar mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-6.
4. Ho YL, Wu CC, Lin LC, Huang CH Chen WJ. Assesment of the coronary artery disease and systolic dysfunction in hypertensive patients with the dobutamine-atropinestress echocardiography effect of the left ventricular hypertrophy. Cardiology. 1998; 95:1592-600.
5. Dorn GW 2nd, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res. 2003;92:1171-5.
6. Komuro I. Molecular mechanism of cardiac hypertrophy and development. Jpn Circ J. 2001;65:353-8.
7. Díez J, López B, González A, Ardanaz N, Fortuño MA. Genética y biología molecular en cardiología (IV). Respuestas del miocardio al estrés biomecánico. Rev Esp Cardiol. 2001;54:507-15.
8. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997; 59:551-71.
9. Anversa P, Leri A. Kajstura. J, Nadal-Ginard B. Myocyte growth and cardiac repair. J Mol Cell Cardiol. 2002;34:91-105.
10. Beltrani AP, Urbanek K, Kajstura J, Yan SK Finato N. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med. 2001;344:1750-7.
11. Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Myocyte death, growth and regeneration in cardiac hypertrophy and failure. Circ Res. 2003;92:139-50.
12. Molkentin JD, Dorn GW. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001;63:391-426.
13. Passier R, Zeng H, Frey N, Naya FJ, Nicol RL. CaM kinase signaling induces cardiac hypertrophy and activates the MEF-2 transcription factor in vivo. J Clin Invest. 2000;105:1395-406.
14. Babu GJ, Lalli MJ, Sussman MA, Sadoshima J, Periasamy M. Phosphorylation of elk-1 by MEK/ERK pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy. J Mol Cell Cardiol. 2000;32:1447-57.
15. Liang F, Lu S, Gardner DG. Endothelin-dependent and - independent components of strain-activated brain natriuretic peptide gene transcription require extracellular signal regulated kinase and p38 mitogen-activated protein kinase. Hypertension. 2000; 35:188-92.
16. Morimoto T, Hasegawa K, Kaburagi S, Kalkita T, Wada H. Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J Biol Chem. 2000;275:13721-6.
17. Mo Y, Ho W, Johnston K, Marmorstein R. Crystal structure of a ternary SAP-1/SRF/c-fos SRE DNA complex. J Mol Biol. 2001; 314:495-506.
18. Sepúlveda JL, Vlahopoulos S, Iver D, Belaguli N, Schwartz RJ. Combinatorial expression of GATA4, Nkx2-5, and serum response factor directs early cardiac gene activity. J Biol Chem. 2002;277:25775-82.
19. Huxley AF. Muscular contraction. J Physiol. 1974;243:1-43.
20. Sheetz MJ. Cell contpapel by membrane-cytoskeleton adhesion. Nat Rev Mol Cell Biol. 2001;2:392-6.
21. Matsuda N, Hagiwara N, Shoda M, Kasanuki K, Hosoda S. Enhancement of the L-type Ca2+ current by mechanical stimulation in single rabbit cardiac myocytes. Circ Res. 1996;78:650-9.
22. Sasaki N, Mitsuiye T, Wang Z, Noma A. Increase of the delayed rectifier K+ and Na(+)-K+ pump currents by hypotonic solutions in guinea pig cardiac myocytes. Circ Res. 1994;75:887-95.
23. Ross RS, Borg TK. Integrins and the myocardium. Circ Res. 2001;88:1112-9.
24. Sadoshima J, Qiu Z, Morgan JP. Tyrosine kinase activation is an immediate and essential step in hypotonic cell swelling-induced ERK activation and c-fos gene expression in cardiac myocytes. EMBO J. 1996;15:5535-46.
25. Epstein ND, Davis JS. Sensing stretch is fundamental. Cell. 2003;112:147-50.
26. Knoll R, Hoshijima M, Hoffman HM, Person V, Lorenzen-Schmidt I. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell. 2002;111:943-55.
27. Frey N, Richardson JA, Olson EN. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc Natl Acad Sci USA. 2000;97:14632-7.
28. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 2004; 37:449-71.
29. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol. 2001;229:141-62.
30. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999;341:1276-83.
31. Mehra MR, Uber PA, Francis GS. Heart failure therapy at a crossroad: are there limits to the neurohormonal model. J Am Coll Cardiol. 2003;41:1606-10.
32. Lijnen P, Petrov V. Renin-angiotensin system hypertrophy and gene expression in cardiac myocytes. J Mol Cell Cardiol. 1999; 31:949-70.
33. Kajstura J, Zhang X, Liu Y, Szoke E, Cheng W. The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation. 1995; 92:2306-17.
34. Dorn GW 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005;115:527-37.
35. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1995; 269:E657-62.
36. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension. 1999;33:981-6.
37. Takeda Y, Yoneda T. Demura M, Usukura M, Mabuchi H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation. 2002;105:677-9.
38. Takeda, Y. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist Hypertens Res. 2004;27:781-9.
39. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002;970:89-100.
40. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355-64.
41. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-8.
42. Blum A. Miller H. Pathophysiological role of cytokines in congestive heart failure. Annu Rev Med. 2001;52:15-27.
43. Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6:95-103.
44. Kanda T, Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J. 2004;45:183-93.
45. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A. 1995;92:4862-6.
46. Kaneko K, Kanda T, Yokoyama T, Nakazato Y, Iwasaki T. Expression of interleukin-6 in the ventricles and coronary arteries of patients with myocardial infarction. Res Commun Mol Pathol Pharmacol. 1997;97:3-12.
47. Maisch B. Extracellular matrix and cardiac interstitium: restriction is not a restricted phenomenon. Herz. 1995;20:75-80.
48. Weber KT. Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. J Hypertens. 2004;22:47-50.
49. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 2001;89:201-10.
50. Weber KT, Pick R, Jalil JE, Janicki JS, Carroll EP. Patterns of myocardial fibrosis. J Mol Cell Cardiol. 1989;21 Suppl 5:121-31.
51. Tomasek A Gabbiani G, Hinz B. Chaponnier C. Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3:349-63.
52. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol. 1999;277:C1-9.
53. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002; 91:1103-13.
54. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79:215-62.
55. Vatner DE, Yang GP, Geng YJ, Asai K, Yun JS. Determinants of the cardiomyopathic phenotype in chimeric mice overexpressing cardiac Gsalpha. Circ Res. 2000;86:802-6.
56. Matsusaka T, Katori H, Inagami T, Fogo, A, Ichikawa I. Communication between myocytes and fibroblasts in cardiac remodeling in angiotensin chimeric mice. J Clin Invest. 1999; 103: 1451-8.
57. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000;102:IV14-23.
58. Vandenburgh HH. Mechanical forces and their second messengers in stimulating cell growth in vitro. Am J Physiol. 1992;262: 350-5.
59. Sigurdson W, Ruknudin A, Sachs F. Calcium imaging of mechanically induced fluxes in tissue-cultured chick heart: role of stretch-activated ion channels. Am J Physiol. 1992;262:H1110-5.
60. Naruse K, King GL. Protein kinase C and myocardial biology and function. Circ Res. 2000;86:1104-6.
61. Hahn HS, Yussman MG, Toyokawa T, Marreez Y, Barrett TJ. Ischemic protection and myofibrillar cardiomyopathy: dose-dependent effects of in vivo deltaPKC inhibition. Circ Res. 2002; 91:741-8.
62. Inagaki Chen L, Ikeno F, Lee FK Imahashi K. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation 2003; 108:2304-7.
63. Mochly-Rosen D, Wu G, Hahn H, Osinska H, Liron T. Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation. Circ Res. 2000;86: 1173-9.
64. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest. 1997;100:2189-95.
65. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the contpapel of NF-[kappa]B activity. Annu Rev Immunol. 2000; 18:621-63.
66. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A. 2003; 100: 12355-60.
67. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A. 2002;99: 12333-8.
68. Matsui T, Li L, Wu JC, Cook SA, Nagoshi T. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem. 2002;277:22896-901.
69. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000;19:2537-48.
70. Yussman MG, Toyokawa T, Odley A, Lynch RA, Wu G. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med. 2002;8:725-30.
71. Sakata Y, Hoit BD, Liggett SB, Walsh RA, Dorn GW. Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation. 1998;97:1488-95.
72. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A. 1998; 95:10140-5.
73. Amin JK, Xiao L, Pimentel DR, Pagano PJ, Singh K. Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol. 2001;33:131-9.
74. Pimentel DR, Amin JK, Xiao L, Miller T, Viereck J. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res. 2001;89:453-60.
75. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18:655-73.
76. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol. 2002;34:379-88.
77. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental, myocardial infarction in mice: role of oxidative stress. Circ Res. 2000;87:392-8.
78. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000; 86:494-501.
79. Babior BM. Activation of the respiratory burst oxidase. Environ Health Perspect. 1994;102 Suppl 10:53-6.
80. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002;40:477-84.
81. Tanaka K, Honda M, Takabatake T. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol. 2001;37:676-85.
82. Clerk A, Sugden PH. Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circ Res. 2000;86:1019-23.
83. Luo JD, Zhang WW, Zhang GP, Guan JX, Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol. 1999;26:903-8.
84. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy3-methylglutaryl coenzyme a reductase inhibitor. Circulation. 2001;104:576-81.
85. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;105:868-73.
86. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem. 1995;270:23173-8.
87. Fuller SJ, Gillespie-Brown J, Sugden PH. Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell sin in neonatal rat ventricular myocytes. J Biol Chem. 1998;273:18146-52.
88. Abdellatif M, Packer SE, Michael LH, Zhang D, Chamg MJ. A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: implications for cardiac hypertrophy. Mol Cell Biol. 1998; 18:6729-36.
89. Jalil JE, Lavandero S, Chiong M, Ocaranza MP. Rho/Rho kinase transductional pathway in cardiovascular disease and remodeling. Rev Esp Cardiol. 2005;58:951-61.
90. Charron F, Tsimiklis; G, Arcand M, Robitaille L, Liang Q. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev. 2001;15:2702-19.
91. Sah VP, Hoshijima M, Chien KR, Brown JH. Rho is required for Galphaq and alphal-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem. 1996;271:31185-90.
92. Arai A, Spencer JA, Olson E. STARS, a striated muscle activator of Rho signaling and serum response factor-dependent transcription. J Biol Chem. 2002;27:24453-9.
93. Yoshida H, Karmazyn M. Na(+)/H(+) exchange inhibition attenuates hypertrophy and heart failure in 1-wk postinfarction rat myocardium. Am J Physiol Heart Circ Physiol. 2000;278: H300-4.
94. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Amin Rev Physiol. 2003;65:45-79.
95. Cingolani HE, Camilion de Hurtado MC. Na(+)-H(+) exchanger inhibition: a new antihypertrophic tool. Circ Res. 2002;90:751-3.
96. Kusumoto K, Haist JV, Karmazyn M. Na(+)/H(+) exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats. Am J Physiol Heart Circ Physiol. 2001;280: H738-45.
97. Del Monte F, Williams E, Lebeche D, Schmidt U, Rosenzweig A. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation. 2001; 104:1424-9.
98. Del Monte F, Harding SE, Dec GW, Gwathmey JK, Hajjar RJ. Targeting phospholamban by gene transfer in human heart failure. Circulation. 2002;105:904-7.
99. Wilkins BJ, Molkentin JD. Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol. 2002;541: 1-8.
100. Sotiropoulos A, Gineitis D. Copeland J, Treisman R. Signal-regulated activation of serum response factor is mediated by changes in actin dynamics. Cell. 1999;98:159-69.
101. Wang D, Chang PS, Wang Z, Sutherland L, Richardson JA. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell. 2001;105:851-62.
102. Komuro I, Kaida T, Shibazaki Y. Streching cardiac myocytes stimulates protooncogene expression. J Biol Chem. 1990;265: 3595-8.
103. Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A. 1998;85:339-43.
104. Schunkert H, Jahn L, Izumo S, Apstein CS, Lorell BH. Localization and regulation of c-fos and c-jun in protooncogene induction by systolic wall stress in normal and hypertrophied rats hearts. Proc Natl Acad Sci U S A. 1992;88:11480-4.
105. Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene expression during myocardial grow and hypertrophy: molecular studies of an adaptative physiologic response. FASEB J. 1991;5:3037-46.
106. Komuro I, Kurabayashi M, Takaku F, Yasaki Y. Expression of cellular oncogene in the myocardium during the developmental stage and pressure overload hypertrophy of the rats. Circ Res. 1988;62:1075-9.
107. Chien KR, Zhu H, Knowlton KU. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol. 1993; 55:77-95.
108. Kariya K, Karns LR, Simpson PR. An enhancer core element mediates stimulation of the rat beta-myosin heavy chain promoter by an alpha 1-adrenergic agonist and activated beta-protein kinase C in hypertrophy of cardiac myocytes. J Biol Chem. 1994; 269:3775-82.
109. Kernan M, Cowan D, Zuker C. Genetic dissection of mechanosensory transduction: mechanoreception-defective mutations of Drosophila. Neuron. 1994;12:1195-206.
110. Molkentin JD, Olson EN. GATA4: a novel transcriptional regulator of cardiac hypertrophy? Circulation. 1997;96:3833-5.
111. Evans SM, Yan W, Murillo MP, Ponce J, Papalopulu N. Tinman, a Drosophila homeobox gene required for heart and visceral mesoderm specification, may be represented by a family of genes in vertebrates: XNkx-2.3, a second vertebrate homologue of tinman. Development. 1995;121:3889-99.
112. Chen Z, Friedrich GA, Soriano P. Transcriptional enhancer factor 1 disruption by a retroviral gene trap leads to heart defects and embryonic lethality in mice. Genes Dev. 1994;8:2293-301.
113. Chen F, Kook H, Milewski R, Gitler A, Lu M, Li J et al. Hop is an unusual homoebox gene that modulates cardiac development. Cell. 2002; 110:713-23.
114. Arsenian S, Wienhold B, Oelgeschlager M. Serum response factor is essential for mesoderm formation during mouse embryo-genesis. EMBO J. 1998; 17:6289-99.
115. Norman C, Runswick M, Pollock R, Treisman R. Isolation and properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos serum response element Cell. 1988;55:989-1003.
116. Nurrish SJ, Treisman R. DNA binding specificity determinants in MADS-box transcription factors. Mol Cell Biol. 1995;15: 4076-85.
117. Shin CH. Modulation of cardiac growth and development by Hop, an unusual homeodomain protein. Cell. 2002; 110:725-35.
118. Flesch M. On the trail of cardiac specific transcription factors. Cardiovasc Res. 2001;50:3-6.
119. Sack MN, Disch DL, Rockman HA. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc Natl Acad Sci U S A. 1997;94:6438-43.
120. Dellow KA, Bhavsar PK, Brand NJ, Barton P. Identification of novel, cardiac-restricted transcription factors binding to a CACC-box within the human cardiac troponin 1 promotor. Cardiovasc Res. 2001;50:24-33.
121. Akasawa H, Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res. 2003;92:1079-88.
122. Depre C, Shipley GL, Chen W, Han Q, Doenst T. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med. 1998;4:1269-75.
123. Sack MN, Rader TA, Park S, Bastin J, McCune SA. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 1996;94:2837-42.
124. Kliewer SA, Xu BE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horn Res. 2001;56:239-63.
125. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr Rev. 1999;20: 649-88.
126. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology. 2001;142:4195-202.
127. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 2000;105: 1723-30.
128. Kanda H, Nohara R, Hasegawa K, Kishimoto C, Sasayama S. A nuclear complex containing PPARalpha/RXRalpha is markedly downregulated in the hypertrophied rat left ventricular myocardiurn with nomial systolic function. Heart Vessels. 2000;15:191-6.
129. Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y. Goto K. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond). 2002; 103 Supp] 48: S284-8.
130. Jamshidi Y, Montgomery HE, Hense HW, Myerson SG, Torra IP Peroxisome proliferator-activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation. 2002;105:950-5.
131. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:52-7.
132. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN. Effect of peroxisome proliferator-activated receptor-alpha and - gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vase Biol. 2003;23:45-51.
133. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 2002;105:1240-6.
134. Takano H, Hasegawa H, Nagai T, Kormuro I. The role of PPAR-gamma-dependent pathway in the development of cardiac hypertrophy. Drugs Today. 2003;39:347-57.
135. Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000;10:238-45.
136. Kiec-Wilk B, Dembinska-Kiec A. Olszanecka A, Bodzioch M, Kawecka-Jaszcz K. The selected pathophysiological aspects of PPARs activation. J Physiol Pharmacol. 2005;56:149-62.
137. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res. 2004;95:568-78.
138. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Gene Dev. 1998;12:599-606.
139. Jenuwein T, Allis C. Translating the histone code. Science. 2001;293:1074-80.
140. Fischle W, Wang Y, Allis C. Histone and chromatin cross-talk. Cuff Opin Cell Biol. 2003; 15:172-3.
141. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang C. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem. 2003;278:28930-7.
142. Hamamori Y, Schneider MD. HAT off to Hop: recruitment of a class I histone deacetylase incriminates a novel transcriptional pathway that opposes cardiac hypertrophy. J Clin Invest 2003; 112:824-6.
143. Kook H, Lepore J, Gitler AD, Lu M, Yung W. Cardiac hypertrophy and histone deacetylase-dcpendent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 2003; 112:863-71.
144. Zhang CI. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002; 110:479-88.
145. Minucci S, Nervi C, Lo Coco F, Pelicci P. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leucemias? Oncogen. 2001;20:3110-5.
146. Kwon HJ, Kim M, Kim DH. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol. 2003;36:110-9.
147. Friddle CJ, Kogan T, Rubin EM, Bristow J. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Nad Acad Sci U S A. 2000; 97:6745-50.
148. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BPI/ eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004;24:200-16.
149. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBPI/eIF4E. Genes Dev. 2002;16:1472-87.
150. Russell B, Motlagh D, Ashley WW. Form follows function: how muscle shape is regulated by work. J Appl Physiol. 2000; 88:1127-32.
151. Perhonen M, Sharp WW, Russell B. Microtubules are needed for dispersal of alpha-myosin heavy chain mRNA in rat neonatal cardiac myocytes. J Mol Cell Cardiol. 1998;30:1713-22.
152. Russell B, Wenderoth NP, Goldspink PH. Remodeling of myofibrils: subcellular distribution of myosin heavy chain mRNA and protein. Am J Physiol. 1992;262:R339-45.
153. Harris BN, Li H, Terry M, Ferrari MB. Calcium transients replate titin organization during myofibrillogenesis. Cell Motil Cytoskeleton. 2005;60:129-39.
154. Klauke N, Smith GL, Cooper JM. Stimulation of isolated ventricular myocytes withm an open architecture microarray. IEEE Trans Biomed Eng. 2005;52:531-8.
155. Borisov AB, Kontrogianni-Konstantopoulos A, Bloch RJ, Westfall MV, Russell MW. Dynamics of obscurin localization during differentiation and remodeling of cardiac myocytes: obscurin as an integrator of myofibrillar structum. J Histochem Cytochem. 2004;52:1117-27.
156. Moncman CL, Wang K. Targeted disruption of nebulette protein expression alters cardiac myofibril assembly and function. Exp Cell Res. 2002;273:204-18.
157. Young P, Ehler E, Gautel M. Obscurin, a giant sarcomeric Rho guanine nucleotide exchange factor protein involved in sarcomere assembly. J Cell Biol. 2001;154:123-36.